In the United States, Ipamorelin and CJC-1295 are not approved by the FDA for human consumption, meaning they are legally sold only for research purposes
has received consulting fees on behalf of Newcastle University from 89bio, Akero, Alimentiv, AstraZeneca, Axcella, Boehringer Ingelheim, Bristol Myers Squibb, Galmed, Genentech, Genfit, Gilead, GlaxoSmithKline, Hanmi, HistoIndex, Intercept, Inventiva, Ionis, IQVIA, Janssen, Madrigal, Medpace, Merck, NGMBio, Novartis, Novo Nordisk, PathAI, Pfizer, Pharmanest, Poxel, Prosciento, Resolution Therapeutics, Ridgeline Therapeutics, Roche, RTI, Shionogi and Terns Pharmaceuticals
The Guideline 2024 multi-society guidance endorses continuing GLP-1 receptor agonists for most patients when teams evaluate and mitigate risk
The telehealth GLP-1 category includes both FDA-approved branded medications and compounded alternatives prepared by licensed pharmacies - and understanding the distinction between them is one of the most important steps a patient can take before enrolling
Key Specs Peptide class: growth hormone secretagogue Research context: ghrelin receptor signaling References: PubChem, PubMed [1,2] Referenced Citations PubChem, Ipamorelin: PubMed, Ghrelin receptor agonists: Receptor Selectivity Ipamorelin is frequently discussed for its receptor specificity compared to other secretagogues [1]
Drugs Affecting Blood and Blood Formation
